NCT03740529 2026-01-27A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLEli Lilly and CompanyPhase 1/2 Completed803 enrolled 2 FDA
NCT02631044 2024-06-27Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)Juno Therapeutics, a Subsidiary of CelgenePhase 1 Completed387 enrolled 2 FDA
NCT01897571 2024-03-26Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCLIpsenPhase 1/2 Completed400 enrolled 22 charts 2 FDA